In 2026, p-tau217 blood testing can help determine whether amyloid plaques associated with Alzheimer’s disease are likely present in a person who already has symptoms of cognitive decline. It cannot, by itself, diagnose Alzheimer’s disease, and it is not intended to screen people without symptoms. For example, if a 68-year-old develops worsening memory problems, a specialist may use a p-tau217-based result alongside the medical history, cognitive testing, examination, and brain imaging to decide whether amyloid PET or cerebrospinal fluid testing is needed. Patients should also distinguish “FDA-cleared” from “FDA-approved.” On May 16, 2025, the FDA cleared Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio through the 510(k) pathway.
It was the first blood test cleared in the United States to aid Alzheimer’s diagnosis, but it is an in-vitro diagnostic that assists in identifying amyloid pathology—not a stand-alone Alzheimer’s test. The clearance applies to this specific laboratory assay and should not be taken to mean that every commercially available p-tau217 test has undergone FDA review. The distinction matters because p-tau217 blood tests differ in their methods, thresholds, regulatory status, and supporting evidence. Patients considering testing in 2026 should ask exactly which assay is being ordered, why it is appropriate for their symptoms, how uncertain results will be handled, and whether any product correction or recall affects the reagents used by the laboratory.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Is a p-Tau217 Alzheimer’s Blood Test?
- FDA Clearance, Intended Use, and the Age-Label Discrepancy
- What Positive, Negative, and Intermediate Results Mean
- How to Prepare for Testing and Discuss the Result
- Performance Limits, False Results, and Study Representation
- The 2025–2026 Lumipulse Reagent Recall
- Availability After the Reagent Correction
- Frequently Asked Questions
What Is a p-Tau217 Alzheimer’s Blood Test?
Tau is a protein found in nerve cells. In Alzheimer’s disease, biological changes involving amyloid and tau begin before dementia becomes severe. One measurable form, phosphorylated tau at threonine 217—usually shortened to p-tau217—tends to rise in the blood when Alzheimer’s-related amyloid pathology is present. That makes it a useful biomarker, but a biomarker is evidence of a biological process rather than a complete clinical diagnosis.
The FDA-cleared Lumipulse test measures both p-tau217 and beta-amyloid 1-42 in K2EDTA human plasma. The separate measurements are combined into a numerical p-tau217/β-amyloid 1-42 ratio and processed on the LUMIPULSE G1200 system. This differs from a blood assay that reports p-tau217 alone, so patients should not assume that results from different products are interchangeable. A useful comparison is a cholesterol test: an elevated cholesterol value can reveal cardiovascular risk, but it does not prove that a person has a blocked coronary artery or explain chest pain on its own. In a similar way, an amyloid-associated blood-test result can strengthen or weaken suspicion of Alzheimer’s pathology, while the diagnosis still depends on symptoms, clinical findings, and other relevant tests.
FDA Clearance, Intended Use, and the Age-Label Discrepancy
The cleared Lumipulse assay is intended to aid clinicians in identifying amyloid pathology in people who present with symptoms of cognitive decline in a specialized-care setting. The FDA explicitly states that it is not for population screening or stand-alone diagnosis. A healthy person ordering a commercial p-tau217 test simply because a parent had Alzheimer’s would therefore be using testing in a substantially different context from the FDA-reviewed intended use. There is also an age discrepancy in the FDA’s public materials. The May 2025 press announcement describes the test as intended for symptomatic adults age 55 and older, while the FDA’s 510(k) clearance summary states age 50 and older.
Patients and clinicians should consult the laboratory’s current authorized labeling rather than treating either cutoff as universally settled. Age criteria may also differ for p-tau217 assays that were not covered by this clearance. The word “cleared” deserves attention. A 510(k) clearance is an FDA regulatory determination for a particular device and intended use; it is not the same term as FDA approval. A clinic’s statement that it offers an “FDA-approved Alzheimer’s blood test” would therefore be inaccurate for this product. Patients should request the assay’s full name and regulatory status, especially when a website refers broadly to an “Alzheimer’s blood test” without explaining its limitations.
What Positive, Negative, and Intermediate Results Mean
A positive Lumipulse ratio is consistent with likely amyloid pathology, but it does not establish that Alzheimer’s disease is the cause of a person’s symptoms. Amyloid can be present in someone whose cognitive problems have another major contributor, and diagnosis still requires clinical interpretation. For example, a patient with a positive result may also have medication side effects, sleep apnea, vascular brain injury, depression, or another condition affecting cognition. A negative result suggests that amyloid pathology is less likely and should prompt clinicians to consider other causes of cognitive decline.
It does not make the patient’s symptoms unimportant, nor does it guarantee that every Alzheimer’s-related process has been excluded. A negative result in someone with rapidly worsening cognition might shift attention toward neurologic disease, metabolic problems, infection, medication effects, or structural abnormalities rather than ending the evaluation. An intermediate or indeterminate result does not provide a dependable yes-or-no answer. The FDA-cleared interpretation calls for further testing in that situation, which may include amyloid PET imaging or analysis of cerebrospinal fluid obtained by lumbar puncture. A patient who receives an intermediate result should ask what confirmatory test is recommended, how quickly it is needed, and whether the blood sample or assay performance could have contributed to the uncertainty.
How to Prepare for Testing and Discuss the Result
Before the blood draw, patients should ask what decision the result is expected to change. A specialist may order the test to determine whether amyloid confirmation is warranted, to clarify an uncertain diagnostic evaluation, or to assess possible eligibility for an Alzheimer’s treatment that requires evidence of amyloid. Testing offers less practical value when no clinician is prepared to interpret the result or arrange the next step.
Patients should bring an up-to-date medication list, a description of when symptoms began, and—when possible—a relative or friend who has observed the cognitive changes. The broader assessment may include cognitive testing, neurologic examination, laboratory work for reversible contributors, and structural brain imaging. A blood biomarker is generally easier to obtain than cerebrospinal fluid and less resource-intensive than amyloid PET, but convenience comes with a tradeoff: uncertain or clinically inconsistent results may still require one of those confirmatory methods. At the results visit, useful questions include: Was the result positive, negative, or intermediate? What numerical value and interpretation did the laboratory report? Does the result fit the symptoms and other findings? Was the specific assay FDA-cleared for this use? Would PET or cerebrospinal fluid testing change the diagnosis or treatment plan? Patients should be cautious if a clinician proposes major treatment solely from a blood value without integrating clinical information.
Performance Limits, False Results, and Study Representation
In the FDA-reviewed study, 499 adults with cognitive impairment were compared against amyloid PET imaging or cerebrospinal fluid findings. Among people with a positive blood-test result, 91.7% were amyloid-positive by PET or cerebrospinal fluid. Among those with a negative result, 97.3% were negative by those reference methods, and fewer than 20% of participants received an indeterminate result. These figures are predictive values in that particular study population, not a universal “accuracy rate” that will apply in every clinic. The study participants were ages 52 to 93. The cohort included 58.1% with Alzheimer’s disease, 30.9% with mild cognitive impairment, and 9.8% with subjective cognitive decline; people with other neurologic diseases were not included.
In addition, 84.8% of participants were White. Performance may differ in more diverse populations, in primary care, among people with other neurologic conditions, or when the proportion of patients with amyloid pathology is lower. The FDA identifies false positives and false negatives as the principal risks. A false positive can lead to distress, unnecessary expense, inappropriate diagnosis or treatment, avoidable treatment effects, and delay in finding the actual cause of symptoms. A false negative can delay effective evaluation and treatment. These risks are one reason the test should not be used as casual screening in people without cognitive symptoms.
The 2025–2026 Lumipulse Reagent Recall
Patients should be aware of an open Class II recall involving specified lots of Lumipulse p-tau217 reagent. FDA recall Z-1302-2026 was initiated on December 11, 2025, posted on February 5, 2026, and remained listed as open on the database page updated July 25, 2026. According to the FDA, affected lots could produce falsely elevated positive or indeterminate ratios and showed low specificity.
This does not mean every Lumipulse result was affected. The issue concerns specified reagent lots, so a patient with a result from the relevant period can ask the laboratory whether an affected lot was used and whether retesting is advisable. That question is especially important when a positive or indeterminate result conflicts with the clinical picture or subsequent PET or cerebrospinal fluid findings.
Availability After the Reagent Correction
Labcorp reports that it temporarily withdrew the Lumipulse assay after the December 2025 reagent problem. According to the laboratory, the manufacturer reported corrective action in April 2026, after which Labcorp conducted its own validation and reinstated the test. This is a laboratory and provider statement; it is not the same as FDA termination of the recall, which remained open in the FDA database as of July 25, 2026.
Availability can therefore vary by laboratory and location. For example, one laboratory may have resumed testing with corrected and independently validated materials while another may use a different p-tau217 assay or continue referring patients for PET or cerebrospinal fluid testing. The ordering clinician or laboratory should be able to identify the assay, platform, specimen requirements, regulatory status, and whether the reagent lot is affected by an active correction.
Frequently Asked Questions
Can a positive p-tau217 blood test diagnose Alzheimer’s disease?
No. A positive result is consistent with likely amyloid pathology, but it does not establish an Alzheimer’s diagnosis or prove that Alzheimer’s is causing the person’s cognitive symptoms. The result must be interpreted with the history, examination, cognitive assessment, and other testing.
Is the Lumipulse p-tau217 blood test FDA-approved?
No. It was FDA-cleared through the 510(k) pathway on May 16, 2025. Calling it FDA-approved would be inaccurate. The clearance also applies to a specific p-tau217/β-amyloid 1-42 plasma-ratio assay, not to every commercial p-tau217 test.
Should someone without memory symptoms get tested?
The FDA-cleared Lumipulse assay is not intended for screening. Its reviewed use is in symptomatic patients evaluated in a specialized-care setting. Testing an asymptomatic person can generate uncertainty and potential harm without providing a clinical diagnosis.
Does a negative result rule out Alzheimer’s disease?
A negative result makes amyloid pathology less likely, but it is not an absolute exclusion. The clinician should compare it with the person’s symptoms and other findings and investigate alternative causes of cognitive decline.
What should a patient do after an indeterminate result?
The FDA-reviewed interpretation recommends further testing. Depending on the clinical situation, that could involve amyloid PET imaging, cerebrospinal fluid testing, or reassessment of whether the sample or reagent was affected by a known technical issue.
How can a patient find out whether the recall affected a previous test?
Ask the ordering clinician or laboratory for the test date, assay name, testing site, and reagent-lot information. The laboratory can determine whether the sample was processed with one of the lots covered by FDA recall Z-1302-2026 and whether retesting is appropriate.
